ICON Public Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICON Public stock.
View analyst ratings for ICON Public or view top-rated stocks.

Wall Street analysts have given ICON Public a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ICON Public wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ICON Public is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for ICON Public.

ICON Public Limited (NASDAQ:ICLR) announced its quarterly earnings data on Tuesday, April, 27th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.97 by $0.09. The medical research company had revenue of $858.20 million for the quarter, compared to analysts' expectations of $780.49 million. ICON Public had a net margin of 11.49% and a trailing twelve-month return on equity of 20.70%.
View ICON Public's earnings history.

ICON Public's stock was trading at $152.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ICLR shares have increased by 41.7% and is now trading at $216.18.
View which stocks have been most impacted by COVID-19.

ICON Public updated its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided earnings per share (EPS) guidance of 8.400-8.800 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.310. The company issued revenue guidance of $3.40 billion-$3.50 billion, compared to the consensus revenue estimate of $3.24 billion.

10 equities research analysts have issued 12 month price objectives for ICON Public's shares. Their forecasts range from $200.00 to $280.00. On average, they anticipate ICON Public's share price to reach $236.00 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for ICON Public or view top-rated stocks among Wall Street analysts.

147 employees have rated ICON Public CEO Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among ICON Public's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ICON Public include Exact Sciences (EXAS), Bitcoin Group (BTGGF), Incyte (INCY), Charles River Laboratories International (CRL), PPD (PPD), PRA Health Sciences (PRAH), Syneos Health (SYNH), Medpace (MEDP), National Research (NRC), Anavex Life Sciences (AVXL), Starpharma (SPHRY), Inotiv (NOTV), Luna Innovations (LUNA), Auxly Cannabis Group (CBWTF) and AIkido Pharma (AIKI).
View all of ICLR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), The Walt Disney (DIS), The Home Depot (HD) and Johnson & Johnson (JNJ).

ICON Public trades on the NASDAQ under the ticker symbol "ICLR."

ICON Public's stock is owned by a variety of retail and institutional investors. Top institutional investors include Kornitzer Capital Management Inc. KS (0.22%), Todd Asset Management LLC (0.19%), Globeflex Capital L P (0.12%), Natixis Advisors L.P. (0.11%), Captrust Financial Advisors (0.05%) and Handelsbanken Fonder AB (0.04%).

ICLR stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Todd Asset Management LLC, Captrust Financial Advisors, Chartwell Investment Partners LLC, Natixis Advisors L.P., Globeflex Capital L P, We Are One Seven LLC, and Fieldpoint Private Securities LLC.

ICLR stock was purchased by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, FDx Advisors Inc., Tributary Capital Management LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, Handelsbanken Fonder AB, KB Financial Partners LLC, Fayez Sarofim & Co, and Cullen Frost Bankers Inc..

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICLR stock can currently be purchased for approximately $216.18.

ICON Public has a market capitalization of $11.59 billion and generates $2.80 billion in revenue each year. The medical research company earns $332.33 million in net income (profit) each year or $6.53 on an earnings per share basis.

ICON Public employs 15,730 workers across the globe.

The following companies are subsidiares of ICON Public: Addplan Inc., Beacon Bioscience Inc., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, Molecular MD Corp., Oxford Outcomes Ltd, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., and VSK (Kenilworth) Limited.

ICON Public was founded in 1990.

The official website for ICON Public is www.iconplc.com.

ICON Public is headquartered at SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000.

ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at (531) 291-2000.